SPI-62 as a treatment for hypercortisolism related to a benign adrenal tumor (ACSPIRE)
This study evaluates the efficacy, safety, and pharmacological effect of SPI-62 in subjects with hypercortisolism related to a benign adrenal tumor.
- Sponsor: Sparrow Pharmaceuticals
- Contact Person: Frank Czerwiec, MD; email [email protected]
- Who should consider participating: This study is designed for people with Endogenous Cushing’s Syndrome (Cushing’s) seeking new treatments for cortisol excess. SPI-62 targets a major source of intracellular cortisol, and it may be more effective at alleviating symptoms while simultaneously offering a stronger safety and tolerability profile.
- https://clinicaltrials.gov/study/NCT05436639